112 related articles for article (PubMed ID: 36876690)
1. Vorinostat induces G2/M cell cycle arrest in breast cancer cells via upregulation of PTEN.
Alqosaibi AI; Abdel-Ghany S
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(4):1503-1511. PubMed ID: 36876690
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via
Abdel-Ghany S; Raslan S; Tombuloglu H; Shamseddin A; Cevik E; Said OA; Madyan EF; Senel M; Bozkurt A; Rehman S; Sabit H
3 Biotech; 2020 Sep; 10(9):407. PubMed ID: 32904337
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat enhances the therapeutic potential of Erlotinib via MAPK in lung cancer cells.
Alqosaibi AI; Abdel-Ghany S; Al-Mulhim F; Sabit H
Cancer Treat Res Commun; 2022; 30():100509. PubMed ID: 35026535
[TBL] [Abstract][Full Text] [Related]
4. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
[TBL] [Abstract][Full Text] [Related]
5. Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer.
Wu PF; Gao WW; Sun CL; Ma T; Hao JQ
Chin Med J (Engl); 2020 Jun; 133(11):1304-1311. PubMed ID: 32452893
[TBL] [Abstract][Full Text] [Related]
6. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest.
Vijayaraghavalu S; Dermawan JK; Cheriyath V; Labhasetwar V
Mol Pharm; 2013 Jan; 10(1):337-52. PubMed ID: 23215027
[TBL] [Abstract][Full Text] [Related]
7. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rathinavelu A
Cells; 2018 Dec; 8(1):. PubMed ID: 30583560
[TBL] [Abstract][Full Text] [Related]
8. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Huang L; Pardee AB
Mol Med; 2000 Oct; 6(10):849-66. PubMed ID: 11126200
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways.
Shan F; Shao Z; Jiang S; Cheng Z
Cancer Med; 2016 Nov; 5(11):3166-3175. PubMed ID: 27726288
[TBL] [Abstract][Full Text] [Related]
11. SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
Zhu X; Kim DW; Zhao L; Willingham MC; Cheng SY
Endocr Relat Cancer; 2016 Jul; 23(7):521-33. PubMed ID: 27267120
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells.
Lee YJ; Won AJ; Lee J; Jung JH; Yoon S; Lee BM; Kim HS
Int J Med Sci; 2012; 9(10):881-93. PubMed ID: 23155362
[TBL] [Abstract][Full Text] [Related]
13. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells.
Arafa el-SA; Zhu Q; Shah ZI; Wani G; Barakat BM; Racoma I; El-Mahdy MA; Wani AA
Mutat Res; 2011 Jan; 706(1-2):28-35. PubMed ID: 21040738
[TBL] [Abstract][Full Text] [Related]
14. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
15. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
[TBL] [Abstract][Full Text] [Related]
16. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
17. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of suberoylanilide hydroxamic acid (SAHA) on chemoradiation for human cervical cancer cells and its mechanism.
Xing J; Wang H; Xu S; Han P; Xin M; Zhou JL
Eur J Gynaecol Oncol; 2015; 36(2):117-22. PubMed ID: 26050346
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
Arnold NB; Arkus N; Gunn J; Korc M
Clin Cancer Res; 2007 Jan; 13(1):18-26. PubMed ID: 17200334
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone.
Wuerzberger SM; Pink JJ; Planchon SM; Byers KL; Bornmann WG; Boothman DA
Cancer Res; 1998 May; 58(9):1876-85. PubMed ID: 9581828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
